tenalisib

Tenalisib is an orally active, highly selective small molecule inhibitor targeting the delta and gamma isoforms of phosphoinositide 3‑kinase (PI3Kδ/γ), as well as salt-inducible kinase 3 (SIK3). It is being developed primarily for hematological malignancies, including T-cell lymphomas and various leukemias, and has shown promising efficacy in clinical trials. Tenalisib acts by inhibiting PI3Kδ/γ signaling pathways involved in cell proliferation and survival, particularly in malignant lymphocytes. The drug is under investigation for use both as a single agent and in combination with other therapies such as romidepsin. It was originally developed by Rhizen Pharmaceuticals[2][5][7].

Other names

(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one3-(3-fluorophenyl)-2-((1S)-1-(7H-purin-6-ylamino)propyl)chromen-4-one3-(3-fluorophenyl)-2-[ (1S ) -1-(7H-purin -6 - ylamino ) propyl ] chromen -4-oneTenalisib [INN]